Evidence on the chemopreventive potential of aspirin and other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) against colorectal cancer is based on experimental cancer in rodents, interventional studies in patients with familial adenomatous polyposis, and some, but not all, epidemiologic investigations.1 As NSAID use may result in serious renal and gastrointestinal side effects, particularly in the elderly, recommendations on chemoprevention with NSAIDs and the optimal regimen must await efficacy-to-toxicity and risk-to-benefit analyses in prospective controlled trials.
Peleg II, Wilcox CM. Aspirin and the Risk of Digestive Cancers-Reply. Arch Intern Med. 1995;155(2):214-217. doi:10.1001/archinte.1995.00430020107017